Renaissance Capital logo

Gracell Biotechnologies Priced, Nasdaq: GRCL

Phase 1 Chinese biotech developing CAR-T cell therapies for cancer.

Industry: Health Care

Latest Trade: $10.25 0.00 (0.0%)

First Day Return: +31.9%

Return from IPO: -46.1%

Industry: Health Care

We are a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies to address major industry challenges and fulfill unmet medical needs in the treatment of cancer. We aim to disrupt conventional approaches to CAR-T cell therapies with our proprietary technology platforms—FasTCAR and TruUCAR. With FasTCAR, we are able to deliver younger, less exhausted T cells for autologous cell therapies with enhanced activities and next-day manufacturing (22 to 36 hours) versus the industry norm of two to six weeks. Our lead FasTCAR-enabled autologous product candidate, GC012F, has achieved multiple minimal residual disease, or MRD, negative stringent complete responses, or sCR, in relapsed or refractory multiple myeloma, or r/r MM, patients in an ongoing investigator-initiated Phase 1 trial in China. With TruUCAR, we are able to derive T cells from non-HLA-matched healthy donors to generate allogeneic CAR-T cell therapies that are readily available off-the-shelf at lower cost for a broad patient base, including those less suitable for autologous CAR-T cell therapies. Our lead TruUCAR-enabled allogeneic product candidate, GC027, has achieved multiple complete responses, or CR, in relapsed or refractory T cell acute lymphoblastic leukemia, or r/r T-ALL, patients in an ongoing investigator-initiated Phase 1 trial in China.
more less
IPO Data
IPO File Date 12/18/2020
Offer Price $19.00
Price Range $16.00 - $18.00
Offer Shares (mm) 11.0
Deal Size ($mm) $209
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 01/07/2021
Offer Price $19.00
Price Range $16.00 - $18.00
Offer Shares (mm) 11.0
Deal Size ($mm) $209
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Citi
Jefferies
more
Company Data
Headquarters Suzhou, China
Founded 2017
Employees 160
Website www.gracellbio.com

Gracell Biotechnologies (GRCL) Performance